# Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer

> **NCT00789633** · PHASE3 · COMPLETED · sponsor: **AB Science** · enrollment: 353 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Masitinib
- **DRUG:** Placebo
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00789633
- **Lead sponsor:** AB Science
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11-25
- **Primary completion:** 2011-12-23
- **Final completion:** 2012-08-31
- **Target enrollment:** 353 (ACTUAL)
- **Last updated:** 2018-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00789633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00789633, "Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00789633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*